ClearPoint Neuro Misses Q1 Earnings Expectations

The medical tech company reported a wider-than-expected loss per share for the quarter.

Mar. 19, 2026 at 11:34am

Got story updates? Submit your updates here. ›

ClearPoint Neuro, a medical technology company specializing in MRI-guided neurosurgical procedures, reported its Q1 2026 earnings results on Tuesday. The company reported a loss of $0.27 per share, missing analysts' consensus estimate of a $0.22 loss per share by $0.05. ClearPoint Neuro's revenue for the quarter was $10.41 million, in line with the $10.40 million expected by analysts.

Why it matters

ClearPoint Neuro's earnings miss highlights the challenges the company is facing in the competitive medical device market. The company's technology is designed to improve patient safety and outcomes for neurosurgical procedures, but it is still working to gain widespread adoption and profitability.

The details

In its earnings report, ClearPoint Neuro cited a negative return on equity of 137.80% and a negative net margin of 69.08% for the quarter. The company's stock opened at $9.60 on Thursday, down from a 52-week high of $30.10. Several research firms have weighed in on ClearPoint Neuro, with B. Riley Financial boosting its price target to $20.00 and maintaining a 'buy' rating, while Weiss Ratings gave the stock a 'sell (d-)' rating.

  • ClearPoint Neuro reported its Q1 2026 earnings results on Tuesday, March 19, 2026.
  • The company's stock opened at $9.60 on Thursday, March 21, 2026.

The players

ClearPoint Neuro

A medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures.

Joseph Burnett

The CEO of ClearPoint Neuro.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The company's stock performance and ability to improve its financial metrics will be closely watched by investors in the coming quarters.

The takeaway

ClearPoint Neuro's earnings miss underscores the challenges the company faces in the competitive medical device market, as it works to gain wider adoption of its MRI-guided neurosurgical technology and achieve profitability.